The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Inclusion Criteria: 1. Age\>=18Y; 2. Good Organ Function; 3. Expected survival time ≥ 3 months; 4. Advanced BRAF V600 ATC that have been diagnosed histologically; 5. At least one measurable lesion as per RECIST v1.1; 6. ECOG score 0-1. Exclusion Criteria: 1. Pregnant or lactating women; 2. Previous treatment with BRAF inhibitors or MEK inhibitors; 3. A history of other malignancies within two years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin; 4. Severe active infections requiring systemic anti-infective therapy.